FFR

HeartFlow Announces Publication of 10-year Follow-Up Data from the DISCOVER-FLOW Study in the Journal of Cardiovascular Computed Tomography

Retrieved on: 
Mardi, mars 12, 2024
Diagnosis, FACC, Coronary artery disease, Risk, Patient, Atherosclerosis, CTA, Journal, Artificial intelligence, FFR, AI, Fierce, Safety, Trailblazer, CAD, Medical device

MOUNTAIN VIEW, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- HeartFlow, Inc., a leader in non-invasive artificial intelligence (AI) heart care solutions, today announced that 10-year follow-up data from its DISCOVER-FLOW study were published in the Journal of Cardiovascular Computed Tomography.

Key Points: 
  • MOUNTAIN VIEW, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- HeartFlow, Inc., a leader in non-invasive artificial intelligence (AI) heart care solutions, today announced that 10-year follow-up data from its DISCOVER-FLOW study were published in the Journal of Cardiovascular Computed Tomography .
  • The company has spent the last decade working with clinicians to improve CAD diagnosis, making significant progress validated by high quality clinical evidence.
  • HeartFlow’s approach is centered around scientific rigor with peer-reviewed publications to provide confidence and certainty to clinicians and the patients they serve.
  • Together, this comprehensive solution offers valuable data not currently available with other non-invasive diagnostic tools or CTA-based AI analyses.

US monetary policy is more powerful in low economic growth regimes

Retrieved on: 
Mardi, avril 2, 2024
Tao, Research Papers in Economics, Excess, American Economic Journal, Doan, Policy, RT, Interpolation, Economic growth, Absorption, Business, E32, Low, Browning, European Economic Review, UST, NBER, Forecasting, Macroeconomics, European Economic Association, Journal of Monetary Economics, Journal of Applied Econometrics, TVAR, Oxford University Press, Time series, Economic Inquiry, Paper, Linearity, Joshua Angrist, Nobuhiro, Environment, Political economy, Journal of Financial Economics, Rated R, R2, Website, Emi, Energy economics, Probability, Medical classification, Eurozone, Sigismund, Quarterly Journal of Economics, Zero lower bound, History, Nature, Chapter, ZT, Journal of Political Economy, Bocconi University, OLS, Statistics, University of California, Irvine, PDF, Classification, ECB, XS, ITP, Impact, Estimation, DGP, Mark Thoma, Social science, Elsevier, JEL, Cambridge University Press, Real, M1, Research, Textbook, Private sector, FED, Credit, UTT, Literature, Federal Reserve, Knotek, Evelyn Regner, Table, European Central Bank, Chow, FRED, Monetary economics, Wald, Ben Bernanke, Premium, P500, BIS, EWMA, International Economic Review, Federal funds rate, Money, Treasury, C32, The Economic Journal, Federal Reserve Economic Data, Employment, Risk, FFR, Suggestion, FOMC, Monte Carlo method, Sigmoid, VAR, Database, Projection, Ascari, The Journal of Finance, Yield curve, United States Treasury security, Economy, Fed, Figure, NFCI, Financial economics, EXP, Freedom, Central bank, PCE, Monetary policy, American Economic Review, Exercise, Interest, Samuel, URR, Rigidity, Business cycle, XT, Landing slot, Chap, Daron Acemoglu, Markov, Blue chip, Kuttner, Response, Quarterly Journal, YT, Channel, GDP, Standard, Effect, Federal, Cost, Christian Social Union (UK), Journal of Econometrics, Comm, Mark Gertler, Use, Economic statistics, IW, Bank for International Settlements, Finance Secretary (India), UC, Bank, Reproduction, Section, News, Housing, Data, Food industry
Key Points: 

    Cleerly® ISCHEMIA™ Software Device Billable With AMA Category I CPT® Code for Noninvasive Estimates of Fractional Flow Reserve

    Retrieved on: 
    Jeudi, février 22, 2024
    Software, Research, General Health, Data Management, Medical Devices, Technology, Clinical Trials, Science, Cardiology, Biotechnology, FDA, Health, CCTA, Circulant matrix, MD, Physician, Pathology, Food, FFR, American Medical Association, Food and Drug Administration, Patient, Diagnosis, Category, Coronary artery disease, Medical imaging

    The American Medical Association (AMA) defines this service as a complementary augmented intelligence tool for noninvasive estimates of fractional flow reserve (FFR) to assist healthcare professionals in clinical diagnosis and decision making.

    Key Points: 
    • The American Medical Association (AMA) defines this service as a complementary augmented intelligence tool for noninvasive estimates of fractional flow reserve (FFR) to assist healthcare professionals in clinical diagnosis and decision making.
    • The Category I CPT® code is an addition to the Category III CPT® codes (CPT® 0623T, 0624T, 0625T, 0626T) used for reporting Cleerly’s advanced coronary atherosclerosis analysis.
    • “The Cleerly ISCHEMIA software provides noninvasive estimates of FFR values that help healthcare professionals make critical decisions in the management of patients with suspected coronary artery disease,” said James P. Earls, MD, Chief Medical Officer of Cleerly.
    • The application of Cleerly ISCHEMIA supports improvements in physician certainty, guides medical therapy decision making, and reduces unnecessary invasive and non-invasive testing2-6.

    Sirnaomics to Present Latest Developments of STP705 for Focal Fat Reduction at IMCAS World Congress 2024

    Retrieved on: 
    Lundi, février 5, 2024
    Poster, FFR, Plastic surgery, Division, Clinical trial, Therapy, Safety, PNP, RNA interference, University of Miami, Phase, University, Conference

    and SUZHOU, China, Feb. 5, 2024 /PRNewswire/ -- Sirnaomics Ltd. (the "Company", Stock Code: 2257, together with its subsidiaries, the "Group" or "Sirnaomics"), a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, presented the latest developments on Polypeptide Nanoparticle (PNP) platform, and its pipeline program STP705 for Focal Fat Reduction's positive clinical data, at IMCAS World Congress 2024, which is taking place in Paris from February 1st - 3rd, 2024.

    Key Points: 
    • and SUZHOU, China, Feb. 5, 2024 /PRNewswire/ -- Sirnaomics Ltd. (the "Company", Stock Code: 2257, together with its subsidiaries, the "Group" or "Sirnaomics"), a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, presented the latest developments on Polypeptide Nanoparticle (PNP) platform, and its pipeline program STP705 for Focal Fat Reduction's positive clinical data, at IMCAS World Congress 2024, which is taking place in Paris from February 1st - 3rd, 2024.
    • Previously, Sirnaomics had reported that a poster with positive clinical data of STP705 for focal fat reduction (FFR) was presented at the 2023 Fall Clinical Dermatology Conference.
    • The safety and efficacy results of this Phase I study support further investigation of STP705 as a potential alternative to other injectables for FFR.
    • The positive data from the Phase I clinical study has led to the Group advancing the program to the Phase II clinical study stage.

    EPV Expands Utilisation of Hansen’s Trading Solution

    Retrieved on: 
    Mercredi, janvier 24, 2024
    Software, Networks, Other Energy, Professional Services, Utilities, Data Management, Alternative Energy, Energy, Technology, Other Communications, Data Analytics, Communications, HSN, ASX, FCR, Data management, FFR, Part, Power, Partnership, Software as a service, Water, EPV, Renewable energy

    As part of the agreement, EPV will leverage the modular capabilities of Hansen Trade by expanding its utilisation of the trading solution to encompass aFRR and FCR market trading.

    Key Points: 
    • As part of the agreement, EPV will leverage the modular capabilities of Hansen Trade by expanding its utilisation of the trading solution to encompass aFRR and FCR market trading.
    • This expansion builds upon EPV’s current deployment of Hansen Trade Intraday Trading, Day-Ahead Trading and Regulating Power Market (mFRR) operations.
    • With Hansen Trade, EPV will be able to operate in all physical trading marketplaces, including Nord Pool’s Intraday and Day-Ahead markets, as well as the mFRR, aFRR, FCR and FFR markets.
    • Mika Luoto, Head of Operations at EPV, commented: “Over the years, Hansen’s unwavering commitment to product development has consistently surpassed our expectations.

    Haemonetics Corporation Completes Acquisition of OpSens Inc.

    Retrieved on: 
    Mardi, décembre 12, 2023
    TAVR, EBITDA, FFR, Pressure, Acquisition, NYSE, OTCQX, Fractional flow reserve, Toronto Stock Exchange, CAD, Patient, Workflow, Coronary artery disease, GAAP, Diagnosis, Growth, Physician, Hospital, DPR, Medical imaging, Haemonetics

    "Expanding our Hospital portfolio with OpSens' products creates exciting growth and diversification opportunities, while providing immediately accretive financial benefits," said Chris Simon, Haemonetics' President and Chief Executive Officer.

    Key Points: 
    • "Expanding our Hospital portfolio with OpSens' products creates exciting growth and diversification opportunities, while providing immediately accretive financial benefits," said Chris Simon, Haemonetics' President and Chief Executive Officer.
    • "We are pleased to officially welcome OpSens to Haemonetics and look forward to driving greater access to OpSens' essential solutions and benefits for physicians and patients throughout the world."
    • Haemonetics financed the acquisition through a combination of cash-on-hand and a $110 million draw under its revolving credit facility.
    • Following this acquisition, Haemonetics estimates that its net debt to EBITDA ratio, as defined in Haemonetics' existing credit agreement, will be approximately 2.3x.

    iFR and FFR are equally safe to diagnose and treat heart disease according to largest-ever analysis of new real-world, long-term data

    Retrieved on: 
    Jeudi, octobre 26, 2023
    Clinical Science (journal), Gold standard, European Society of Cardiology, AEX, Public sector banks in India, American College, Interventions, NYSE, INT, PHG, Pilot in command, ESC, Pressure, Lund University, Safety, Revascularization, American Heart Association, JACC, Risk, Guideline, MACE, PCI, Blood, FFR, TCT, Patient, Diagnosis, Death, EACTS, American College of Cardiology, Medical device, Pharmaceutical industry, Medical imaging, Cardiology

    iFR is an innovative pressure-derived index only offered by Philips that is used to assess coronary blockages during interventional procedures.

    Key Points: 
    • iFR is an innovative pressure-derived index only offered by Philips that is used to assess coronary blockages during interventional procedures.
    • The analysis, “Long-term Safety of Revascularization Deferral Based on Instantaneous Wave-Free Ratio or Fractional Reserve,” compares patient outcomes using iFR and FFR in the diagnosis and treatment of heart disease.
    • The cumulative MACE risks for each group differentiated by 1.6% (iFR: 21.5%, FFR: 19.9%, HR 1.09 (95% CI: 0.90-1.33 at 5 years).
    • iFR is considered the Gold Standard for hyperemia-free physiologic assessment for measuring pressure in diagnostic and interventional procedures [1,4].

    Haemonetics Corporation Announces Definitive Agreement to Acquire OpSens, Inc.

    Retrieved on: 
    Mardi, octobre 10, 2023
    Pressure, Diagnosis, Hospital, Physician, NYSE, TSX, Acquisition, FFR, Model Business Corporation Act, Piper, Fractional flow reserve, EBITDA, PCI, HVS Global Hospitality Services, TAVR, DLA, DPR, Workflow, Credit agreements in South Africa, DLA Piper, CAD, Growth, Goldman Sachs, Vascular closure device, GAAP, Patient, Coronary artery disease, Pharmaceutical industry, Medical imaging, Fine chemical, Bank, Haemonetics

    BOSTON, Oct. 10, 2023 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, and OpSens, Inc. (TSX:OPS) (OTCQX:OPSSF), a medical device cardiology-focused company delivering innovative solutions based on its proprietary optical technology, today announced that they have entered into a definitive agreement under which Haemonetics will acquire all outstanding shares of OpSens for CAD $2.90 per share in an all-cash transaction representing a fully diluted equity value of approximately USD $253 million at current exchange rate.

    Key Points: 
    • OpSens also manufactures a range of fiber optic sensor solutions used in medical devices and other critical industrial applications.
    • Stewart Strong, President, Global Hospital at Haemonetics, said, "With the acquisition of OpSens, we expand our leadership in interventional cardiology and strengthen our foundation for additional growth and diversification.
    • Following this acquisition, Haemonetics' net debt to EBITDA ratio, per the terms set forth in the Company's existing Credit Agreement, is expected to be approximately 2.1x.
    • Haemonetics posted supplemental slides with additional information about this transaction to Haemonetics' investor relations website.

    New Data from Clinical Studies Further Validate HeartFlow’s All-in-One Portfolio of Precision Coronary Care Solutions

    Retrieved on: 
    Vendredi, juillet 28, 2023
    CT, Plaque, Society, Multifocal stenosing ulceration of the small intestine, Anatomy, Society of Cardiovascular Computed Tomography, CAD, Circulant matrix, CCTA, Physiology, Roadmap, IVUS, FFR, Calcium, SCCT, Patient, Risk, Atherosclerosis, Conference, Medical imaging, Pharmaceutical industry

    MOUNTAIN VIEW, Calif., July 28, 2023 (GLOBE NEWSWIRE) -- Respective results from the REVEALPLAQUE, DECODE, and SMART-CT clinical studies demonstrate the accuracy, utility, and efficiency of HeartFlow’s portfolio of coronary computed tomography angiography (CCTA)-based precision coronary care technologies.

    Key Points: 
    • MOUNTAIN VIEW, Calif., July 28, 2023 (GLOBE NEWSWIRE) -- Respective results from the REVEALPLAQUE, DECODE, and SMART-CT clinical studies demonstrate the accuracy, utility, and efficiency of HeartFlow’s portfolio of coronary computed tomography angiography (CCTA)-based precision coronary care technologies.
    • HeartFlow is the first company to offer a suite of technologies to help clinicians non-invasively identify stenoses in the coronary arteries ( RoadMap™Analysis ), assess coronary blood flow ( FFR C T Analysis ), and characterize and quantify coronary atherosclerosis ( Plaque Analysis ).
    • Together, this comprehensive solution offers valuable data not currently available with traditional non-invasive diagnostics tools, allowing clinicians to see the full picture of their patients’ coronary artery disease (CAD).
    • "Until now, clinicians have not had access to a complete view of a patient’s heart health with accurate data on coronary anatomy, physiology, and plaque.

    Pulse Medical receives FDA Breakthrough Device Designation for its μFR® system

    Retrieved on: 
    Vendredi, mai 26, 2023
    Pressure, Classification, Physiology, MACE, FFR, PCI, Therapy, Patient, Physician, Risk, Diagnosis, FDA, Cardiovascular disease, Death, Breakthrough, Medical device, Medical imaging

    SHANGHAI, May 26, 2023 /PRNewswire/ -- Pulse Medical Technology, Inc. (Pulse Medical) 4th generation μFR® system has received an FDA Breakthrough Device designation.

    Key Points: 
    • SHANGHAI, May 26, 2023 /PRNewswire/ -- Pulse Medical Technology, Inc. (Pulse Medical) 4th generation μFR® system has received an FDA Breakthrough Device designation.
    • Pulse Medical, founded in 2015, located in Shanghai, China, is dedicated to developing innovative technology for precise diagnosis and optimal treatment of patients with pan-vascular disease.
    • Pulse Medical has been pioneering and invented the key algorithm of μFR®, the fast computation methodology of fractional flow reserve (FFR) from multiple imaging data.
    • The classification enables a coordinated and expedited review process with FDA, accelerating the commercialization of Pulse Medical.